stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Net income
Grifols, S.A.'s net income for fiscal 2025 was $695.8M, up 44.8% from $480.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $789.6M. Over the past ten years it has ranged from $242.5M (fiscal 2023) to $1.0B (fiscal 2020); the current reading is higher than 45% of that period. Grifols, S.A. ranks 13th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $695.8M | 44.83% |
| FY2024 | $480.4M | 98.16% |
| FY2023 | $242.5M | (36.30%) |
| FY2022 | $380.6M | (8.20%) |
| FY2021 | $414.6M | (58.69%) |
| FY2020 | $1.0B | 9.67% |
| FY2019 | $915.2M | 6.76% |
| FY2018 | $857.2M | 9.01% |
| FY2017 | $786.4M | (0.30%) |
| FY2016 | $788.7M | 2.91% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $31.5M | (90.52%) |
| Jun 2026 | $332.0M | 288.55% |
| Mar 2026 | $85.4M | (74.93%) |
| Dec 2025 | $340.8M | 4,191.12% |
| 31 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.0B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| GSK GSK PLC Sponsored ADR compare | $6.3B |
| SNY Sanofi compare | $4.5B |
| GRFS Grifols, S.A. | $789.6M |
| BIIB Biogen Inc. compare | $347.5M |
| OGN Organon & Co. compare | $213.0M |
| NSRX Nasus Pharma Ltd. compare | −$14.5M |
| AMRN Amarin Corporation PLC compare | −$19.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GRFS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement